KIT exon 9 GIST has shorter PFS on imatinib 400 mg vs exon 11. Imatinib 800 mg/day (split...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-KIT-EXON9-GIST |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-GIST |
| Sources | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-KIT |
|---|---|
| Variante | exon 9 (domaine extracellulaire — ~10% GIST, principalement de l'intestin grêle) |
| Maladie | DIS-GIST |
| Niveau ESCAT | IB |
| Combinaisons recommandées | imatinib 800 mg/day split BID (1L advanced/metastatic exon 9) |
| Contre-indiqué en monothérapie | imatinib 400 mg/day as 1L for exon 9 (inferior PFS — escalate to 800 mg) |
| Résumé des faits | KIT exon 9 GIST has shorter PFS on imatinib 400 mg vs exon 11. Imatinib 800 mg/day (split 400 mg BID) improves PFS and OS vs 400 mg in this genotype (EORTC-62005 / MetaGIST meta-analysis, Gastrointest Stromal Tumor Meta-Analysis 2010). High dose is standard 1L for exon 9. |
Notes
ESCAT IB. OncoKB Level 1. Source-gap as DIS-GIST. Adjuvant strategy in high-risk resected exon-9 GIST less established — extended- duration imatinib often considered. Exon 9 GIST predominantly small-bowel primary; extra-gastric origin should prompt KIT exon 9 testing if not already done.
Utilisé par
No reverse references found in the YAML corpus.